Satellos wins FDA Fast Track designation

• Satellos (NASDAQ:MSLE) said the FDA granted Fast Track designation to SAT-3247 for Duchenne muscular dystrophy.
• The drug already holds Orphan Drug and Rare Pediatric Disease designations.
• Phase 2 BASECAMP and TRAILHEAD studies are expected to report additional data in 2H 2026.

Satellos Bioscience (NASDAQ:MSLE) said the U.S. Food and Drug Administration has granted Fast Track designation to SAT-3247 for the treatment of Duchenne muscular dystrophy.

The designation is intended to speed development and regulatory review for therapies addressing serious conditions with unmet medical need.

SAT-3247 already holds Orphan Drug and Rare Pediatric Disease designations, adding to its regulatory support profile in Duchenne muscular dystrophy.

The company is currently running Phase 2 BASECAMP and TRAILHEAD studies in both pediatric and adult patients, with additional data expected in the second half of 2026.

Satellos said the program remains focused on improving muscle regeneration in Duchenne muscular dystrophy through a disease-modifying approach.

The company continues to advance SAT-3247 across multiple age groups as part of its broader clinical development strategy.